Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review
- 37 Downloads
Sepsis and septic shock are inflammatory disorders associated with high rates of mortality. Patients with sepsis and septic shock frequently become tachycardic as a result of the utilization of vasopressor therapy and cardiac overcompensation owing to hypotension, predisposing patients to an increased risk of atrial fibrillation. Previously, it was thought that beta-blocker therapy in patients with sepsis would exacerbate hypotension; however, recent studies have shown that may not be the case.
This review aims to ascertain whether beta-blocker therapy reduces heart rate in patients with sepsis without a corresponding decrease in blood pressure, and if beta-blockade has a beneficial effect on mortality.
Several databases including Cochrane, EMBASE, PubMed, SCOPUS, and Web of Science were scoured for trials pertaining to the utilization of beta-blockers in sepsis and septic shock, and trials that were either prospective or controlled were included in this review.
In the initial search, 1839 articles were found, and those were subsequently reduced to 14 trials (five randomized controlled trials, nine non-randomized trials) that were deemed appropriate for inclusion in this review. All included trials displayed beneficial effects on heart rate without any detriments to blood pressure. Of the six trials that assessed mortality, four showed substantial benefits.
The majority of the trials assessed in this review displayed beneficial results for beta-blocker use in patients with sepsis. However, owing to the deficit of large-scale randomized controlled trials addressing this topic, further research is needed to ensure the veracity of these results.
The authors acknowledge Nguyen Le for her assistance in assessing articles for this review.
Compliance with Ethical Standards
No sources of funding were received for the preparation of this systematic review.
Conflict of interest
Young R. Lee, Michael Sadanand Seth, Dylan Soney, and Hanyu Dai have no conflicts of interest that are directly relevant to the content of this systematic review.
- 2.Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.Google Scholar
- 3.Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55. https://doi.org/10.1378/chest.101.6.1644.Google Scholar
- 8.Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928–48. https://doi.org/10.1097/01.CCM.0000139761.05492.D6.Google Scholar
- 9.Sander O, Welters ID, Foëx P, Sear JW. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med. 2005;33(1):81–8. https://doi.org/10.1097/01.CCM.0000150028.64264.14.Google Scholar
- 11.Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://www.handbook.cochrane.org. Accessed 13 Feb 2019.
- 14.Yang S, Liu Z, Yang W, et al. Effects of the β-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(10):714–7. https://doi.org/10.3760/cma.j.issn.2095-4352.2014.10.007.Google Scholar
- 16.Xinqiang L, Weiping H, Miaoyun W, et al. Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(9):759–63. https://doi.org/10.3760/cma.j.issn.2095-4352.2015.09.012.Google Scholar
- 17.Wang S, Li M, Duan J, et al. Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29(5):390–5. https://doi.org/10.3760/cma.j.issn.2095-4352.2017.05.002.Google Scholar
- 18.Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg. 1972;104(1):46–51.Google Scholar
- 22.Tao Y, Jingyi W, Xiaogan J, Weihua L, Xiaoju J. Effect of esmolol on fluid responsiveness and hemodynamic parameters in patients with septic shock [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(11):885–9. https://doi.org/10.3760/cma.j.issn.2095-4352.2015.11.004.Google Scholar
- 29.Lindsay CA, Barton P, Lawless S, et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr. 1998;132(2):329–34.Google Scholar